Development of a near-care diagnostic test for Lyme disease

莱姆病是北美最常见的蜱传疾病。莱姆病新病例 疾病在加拿大各地呈上升趋势，这促使人们提高了对 疾病，并提出了目前用于诊断的测试的问题。当前 测试依赖于检测患者血液中的抗体， 导致莱姆病的细菌。因为这些抗体反应是随着时间的推移而产生的 并且随着感染程度而变化，该测试对于诊断早期感染可能是有问题的， 这可能会延迟抗生素治疗。最近，有一个推动，以确定其他 用于诊断的非抗体莱姆病标记物。这项研究将使用一种敏感的 和强大的蛋白质发现方法，以挖掘血液样本中的新莱姆病标志物 疾病鉴定出的蛋白质将用于开发一种改进的检测莱姆病的方法 疾病

Lyme disease is the most common tick-borne illness in North America. New cases of Lyme disease are on the rise throughout Canada, which has prompted increased awareness of the disease and raised issues with the currently available tests used for diagnosis. The current tests rely on detection of antibodies found in the patients blood that are produced in response to bacteria that cause Lyme disease. Because these antibody responses develop over time and vary with degree of infection, the test can be problematic for diagnosing early infection, which may delay antibiotic therapy. Recently, there has been a push to identify additional non-antibody Lyme disease markers for use in diagnosis. This research will use a sensitive and powerful protein discovery approach to mine blood samples for new markers of Lyme disease. The proteins identified will be used to develop an improved test for detecting Lyme disease.